Is the benefit of adjuvant chemotherapy limited to high risk stage II colorectal cancer ? by Roberto, Michela et al.
gastrointestinal (colorectal) cancers
D24 Is the benefit of adjuvant chemotherapy limited to high-risk
stage ii colorectal cancer?
M. Roberto1, A. Romiti1, E. Pilozzi1, G. Balducci1, M. Ferri2, S. Uccini1, R. Falcone1,
G. Campisi1, P. Mercantini1, F. Mazzuca1, F.R. Di Pietro1, C.E. Onesti1,
A. Botticelli1, P. Marchetti1
1Università degli studi di Roma “La Sapienza”, Roma
2Università degli studi di Roma, Roma
Background: The adjuvant treatment of stage II colorectal cancer (CRC) is not
definitely established. Indeed, according to the lasted clinical practice guidelines, stage
II CRC can be managed with either observation or adjuvant fluoropyrymidines. The
5-years disease free survival (DFS) ranges between 70-80% of cases and the absolute
DFS benefit of adjuvant chemotherapy (ACT) does not overcome 5%. At present,
prognostic parameters such as clinical presentation of disease, T, grading, lymph-node
sampling and lymphovascular invasion (LVI) guide the clinical choice. Moreover, the
role of microsatellite instability (MSI) is controversial as result of heterogeneous and
conflicting data coming from the literature. Aim of the study was to evaluate the
outcome of patients with stage II CRC according to prognostic parameters and the
treatment received.
Patients and methods: Clinical records of patients with stage II CRC, consecutively
observed at our Institution from 2009 to 2015, were reviewed. High-risk stage II was
defined according to the presence of one of the following criteria: T4, G3, LVI or <12
lymph nodes retrieved after surgery. Microsatellite instability (MSI) was evaluated by
amplification of target sequences. Disease-free survival (DFS) was calculated from time
of diagnosis until relapse or death for any cause. Kaplan-Meier method and Cox
regression were performed to analyse the effect of variable on DFS.
Results: A total of 252 patients were included: median age 73 years (range 35-96), 53 %
male and 47 % female, 141 (61%) high-risk and 90 (39%) low-risk. Out of 121 tested
patients: 79% and 21% were MSS and MSI, respectively. Adjuvant chemotherapy was
administered to 93 patients: 78% high-risk and 22% low-risk disease. With a median
follow-up time of 5 years, median DFS was 15.7 months (1-82) in patients treated with
surgery alone and 34.7 months (2-78) in patients receiving ACT. Overall, ACT
significantly reduced the risk of relapse (HR = 0.3, P = 0.005). The benefit of ACT was
in both low-risk (log Rank: 5.87, P = 0.01) and high-risk stage II disease (log Rank:
2.20, P = 0.13). In a multivariate Cox regression model, gender, ACT and T resulted as
independent predictors of DFS (HR= 0.44, 95%CI 0.21-0.96; HR = 0.30, 95%CI
0.13-0.71; HR = 2.86, 95%CI1.24-6.62 respectively).
Conclusions: Adjuvant chemotherapy improved DFS in high-risk as well as low-risk
stage II CRC. Further studies are needed to identify those patients who really need to
undergo adjuvant treatments.
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